On July 31, 2025, Aakash K. Hindocha, Deputy Vice President at Nuvama Professional Clients Group, highlighted three stocks as compelling buys: Jindal Steel, Ajanta Pharma, and Godrej Agrovet in his daily market outlook. 

Jindal Steel stands out on technical strength and sector demand. Noted by analysts like Manas Jaiswal and Axis Securities as a bullish metal play, it's seen benefiting from India’s ongoing infrastructure push and capacity expansion—particularly at Angul. Despite a recent dip in quarterly earnings and muted market sentiment, the firm retains long-term upside potential.

Ajanta Pharma remains a resilient mid-cap with steady fundamentals, though its stock saw a recent dip following earnings. Analysts believe recovery is likely, citing strong export and domestic prescription growth trends.

Godrej Agrovet offers exposure to agribusiness and animal feed demand. Trading at approximately ₹777, it has a consensus target near ₹840, suggesting around 8% upside. Though shares fell up to 12% after recent results, its long-term growth outlook remains intact.

These selections offer sector diversification across metals, pharmaceuticals, and agribusiness—each carrying different drivers of growth and margin potential. Investors seeking midterm returns may find this trio appealing within a balanced portfolio framework.